MK

Mark Krul

Chief Executive Officer at Inthera Bioscience AG

The Randstad, Netherlands

Overview

Work Experience

OA

Oncode Accelerator

  • Chief Scientific Officer

    2024 - Current

CT

Cristal Therapeutics

  • Board Member

    2017

IB

Inthera Bioscience AG

  • Chief Executive Officer

    2024

  • Board Member

    2018 - 2024

AO

Aglaia Oncology Fund II

  • Founder and Director

    2014

  • Director

    2003

Macrophage Pharma Ltd.

  • Board Member

    2017 - 2022

IP

ISA Pharmaceuticals B.V.

  • Chairman Advisory Board

    2004 - 2018

NDDO Oncology

  • Manager drug development

    1997 - 2003

European Cancer Center

  • Research Manager

    1993 - 1997

Education

Investments

Inthera Bioscience

Seed

Total Funding: $20M

Cristal Therapeutics

Series Unknown

Total Funding: $14M

Relevant Websites